Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Blood (2024) 144 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2024-205007

Published: 2024

Journal Articles

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Burhan Ferhanoglu, Zafer Gulbas, Ant Uzay, Muhit Özcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Asu Fergun Yilmaz, Derya Koyun, Nihan Alkis, Elif Birtas Atesoglu

Blood (2022) 140 (Supplement 1): 6704–6705.

https://doi.org/10.1182/blood-2022-165385

Published: 2022

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Michael Northend, William Wilson, Laura Clifton-Hadley, Zaynab Rana, Tanya-Louise Martin, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoglu, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna

Blood (2022) 140 (Supplement 1): 1456–1458.

https://doi.org/10.1182/blood-2022-156790

Published: 2022

Journal Articles

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Burhan Ferhanoglu, Marta Zerga, Mubarak Al-mansour, Tae Min Kim, Su-Peng Yeh, Yuqin Song, Amado J Karduss, Gayane Tumyan, Soon Thye Lim, Silvia Rivas-Vera, Yok Lam Kwong, Kwang-Wei Wu, Zhongwen Huang, Mark Hertzberg

Blood (2021) 138 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2021-145838

Published: 2021

Journal Articles

R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux ®) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience

Murat Ozbalak, Metban Mastanzade, Ozden Ozluk, Tarik Onur Tiryaki, Simge Erdem, Ezgi Pınar Özbalak, Tuğrul Elverdi, Ipek Yonal Hindilerden, Mustafa Nuri Yenerel, Teoman Soysal, Meliha Nalcaci, Burhan Ferhanoglu, Sevgi Kalayoglu Besisik

Blood (2021) 138 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2021-145810

Published: 2021

Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-134885

Published: 2020

Journal Articles

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

Osman Ilhan, Guldane Cengiz Seval, Ferit Avcu, MD, Burhan Ferhanoglu, MD, Güven Çetin, Erdal Kurtoglu, Figen Atalay, MD, Emine Gulturk, Meliha Nalcaci, Meral Beksac, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138899

Published: 2020

Journal Articles

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Blood (2019) 134 (Supplement_1): 5476.

https://doi.org/10.1182/blood-2019-126402

Published: 2019

Journal Articles

Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)

Burhan Ferhanoglu, MD, Tae Min Kim, Gayane Tumyan, DMSc, MD PhD, Su-Peng Yeh, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Amado Karduss, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, FAMS, Mubarak Al Mansour, MD, Silvia Rivas-Vera, MD, Yuqin Song, MD PhD, Marta Zerga, MD, Julie Blair, PhD MD MPhil, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg

Blood (2018) 132 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2018-99-111146

Published: 2018

Journal Articles

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 833.

https://doi.org/10.1182/blood.V130.Suppl_1.833.833

Published: 2017

Journal Articles

Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience

A. Burhan Ferhanoglu, MD, Murat Özbalak, Ayse Salihoglu, MD, Teoman Soysal, MD, ihsan Karadoğan, Semra Paydas, MD, Evren Ozdemir, MD, Birol Yıldız, Nuri Karadurmuş, Leylagül Kaynar, Zeynep Arzu Yeğin, Ezgi Pınar Özbalak, Gülsan Sucak, Vildan Ozkocaman, MD, Pervin Topçuoğlu, Muhit Ozcan, MD, Elif Birtas, Hakan Goker, MD

Blood (2017) 130 (Supplement 1): 5173.

https://doi.org/10.1182/blood.V130.Suppl_1.5173.5173

Published: 2017

Journal Articles

The Comparison of the Autologous Peripheral Blood Stem Cell Mobilization and Collection in Young and Elderly Patients

Ayse Birekul, Ali Unal, Cagri mehmet Unal, Yildizhan Esra, Serdar Sivgin, MD, Turak Esra, Leylagul Kaynar, MD, Bulent Eser, Mustafa Cetin, MD, A. Burhan Ferhanoglu, MD

Blood (2015) 126 (23): 4747.

https://doi.org/10.1182/blood.V126.23.4747.4747

Published: 2015

Journal Articles

Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia

Eda Tanrikulu Simsek, MD, Ahmet Emre Eskazan, MD, Mahir Cengiz, MD, M. Cem Ar, MD PhD, Seda Ekizoglu, PhD, Ayse Salihoglu, MD, Emine Gulturk, MD, Tugrul Elverdi, MD, Seniz Ongoren Aydin, MD, Ahu Senem Demiroz, MD, Ayse Nur Buyru, MD, Zafer Baslar, MD, Ugur Ozbek, MD PhD, A. Burhan Ferhanoglu, MD, Yildiz Aydin, MD, Nukhet Tuzuner, MD Professor, Teoman Soysal, MD

Blood (2015) 126 (23): 2783.

https://doi.org/10.1182/blood.V126.23.2783.2783

Published: 2015

Journal Articles

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii Osmanov, Hyeon-Seok Eom, Max S. Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoglu

Blood (2015) 126 (16): 1893–1901.

https://doi.org/10.1182/blood-2015-03-632430

Published: 2015

Includes: Supplemental data

Journal Articles

Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance

Yucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, PhD, Ayse Salihoglu, Tugrul Elverdi, MD, Sinem Firtina, Suzin Catal Tatonyan, Seniz Ongoren Aydin, Muhlis Cem Ar, Zafer Baslar, Muge Sayitoglu, PhD, A. Burhan Ferhanoglu, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2013) 122 (21): 384.

https://doi.org/10.1182/blood.V122.21.384.384

Published: 2013

Journal Articles

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia

Mustafa Sevinc, Ahmet Emre Eskazan, Aydin Karabulut, Msc, Suzin Catal Tatonyan, Emine Gulturk, Ayse Salihoglu, Seniz Ongoren Aydin, M. Cem Ar, Zafer Baslar, A. Burhan Ferhanoglu, Nukhet Tuzuner, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2011) 118 (21): 4603.

https://doi.org/10.1182/blood.V118.21.4603.4603

Published: 2011

Journal Articles

Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience

Suzan Alp, Ayse Salihoglu, Ahmet Emre Eskazan, Emine Gulturk, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Ayse Nur Buyru, Ugur Ozbek, A. Burhan Ferhanoglu, Yildiz Aydin, Teoman Soysal

Blood (2011) 118 (21): 4429.

https://doi.org/10.1182/blood.V118.21.4429.4429

Published: 2011

Journal Articles

Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience

Murat Ozbalak, M. Cem Ar, Ayse Salihoglu, Emine Gulturk, Ahmet Emre Eskazan, Hematologist, Seniz Ongoren Aydin, Zafer Baslar, Professor Doctor, Teoman Soysal, Professor Doctor, Yildiz Aydin, Professor Doctor, Nukhet Tuzuner, Professor Doctor, A. Burhan Ferhanoglu, Professor Doctor

Blood (2011) 118 (21): 5223.

https://doi.org/10.1182/blood.V118.21.5223.5223

Published: 2011

Journal Articles

Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia

Ahmet Emre Eskazan, Suzin Catal Tatonyan, Ayse Salihoglu, Emine Gulturk, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, A. Burhan Ferhanoglu, Nukhet Tuzuner, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2011) 118 (21): 1692.

https://doi.org/10.1182/blood.V118.21.1692.1692

Published: 2011

NARROW

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux ®) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience

The Comparison of the Autologous Peripheral Blood Stem Cell Mobilization and Collection in Young and Elderly Patients

Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia

Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience

Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience

Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only